Abstract
Background and Objective: The encumbrance of antimicrobial resistance worldwide is substantive and likely to rise without any appropriate treatment which has enhanced the urge for the development of either new antibiotics or adjuvant therapy with antibiotics. Thus, we aimed to study a comparative antibiogram pattern of 758 clinical isolates collected from Pawana Hospital and Accord SDH, Pune (India), towards Elores (a novel antibiotic and adjutant entity of ceftriaxone, sulbactam and disodium edetate) and other antibiotics (imipenem, meropenem and piperacillin + tazobactam).
 Methods: The clinical samples collected from outpatients and inpatients during a period of one year (January, 2018 to January, 2019), from Pawana Hospital and Accord SDH, Pune (India) and were further subjected to bacterial identification. Antibiotic susceptibility testing was executed in accordance with the recommendations of Clinical Laboratory Standards Institute (CLSI) guidelines.
 Results: Out of 758 collected samples, urine samples contributed 69.41 and 37.63% among Enterobacteriaceae and Non-Enterobacteriaceae followed by pus (20.25 and 19.35%) and sputum (4.2 and 19.89%) while <4% and <12% Enterobacteriaceae and Non-Enterobacteriaceae isolates were collected from rest of the specimen. E. coli were found most prevalent (50.13%) along with 19.13 and 16.09% prevalence of Pseudomonas spp. and Klebsiella spp. whereas rest of the pathogens were <7% present. The antibacterial activity of Elores (87.80%) was observed superior to carbapenem drugs (meropenem; 62.67% and imipenem; 60.95%) and far better to piperacillin + tazobactam (48.42%) against 758 clinical pathogens. Antibiogram profile depicted Elores as most susceptible (95.10%) drug towards Enterobacteriaceae isolates which was approximately 31-50% more sensitive than other test drugs. Similar pattern was obtained for Non-enterobacteriaceae isolates (62.90%) where Elores contributed approximately 1-5% higher activity. However, Elores also conquered 79.51-86.59% resistance among meropenem, imipenem and piperacillin + tazobactam resistant pathogens.
 Conclusion: Susceptibility profile data revealed the equivalence of Elores (Antibiotic-adjuvant entity; AAE) with carbapenem drugs (meropenem and imipenem) and superiority over piperacillin + tazobactam against clinical pathogens. Elores was also found active towards meropenem, imipenem and piperacillin + tazobactam resistant pathogens. Therefore, Elores, a resistance breaker, can be used as an efficient treatment alternate towards infections caused by resistant pathogens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
